NewsRoom Articles - Page 3 of 208

TuesdayJun 17, 2025 10:00 am

Study Finds the Overall Prevalence of Psoriasis in the US Unchanged

A recently published analysis that appeared in the Journal of American Academy of Dermatology has concluded that the general percentage of adults in the U.S. diagnosed with psoriasis remains unchanged at 3% over the past 10 years. However, the investigators mention several points of concern that aren’t reflected in this general summary. For starters, they point out that the population in America has expanded. Consequently, a stable overall percentage of individuals diagnosed with psoriasis shouldn’t be taken to mean that the caseload has decreased. For example, at the current U.S. population, 3% translates into approximately 8 million individuals, which is…

TuesdayJun 17, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease

Behçet’s disease is more prevalent in countries along the Silk Road, including Türkiye, Iran and Japan. Even with treatment, symptoms can continue occurring for many patients and significantly affect their quality of life and productivity. Soligenix has initiated a clinical trial to evaluate the safety, tolerability and preliminary efficacy of SGX945 in patients suffering from oral ulcers. Behçet’s disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to a range of symptoms including painful mouth and genital ulcers, eye inflammation and skin lesions. With limited treatment options available, Soligenix (NASDAQ: SNGX) is at the forefront of…

MondayJun 16, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam has developed the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals captured in real time. Patients can have the HeartBeam System with them at all times, ready to record an ECG in 30 seconds at home or anywhere when they feel symptoms to reduce delays in care. The HeartBeam System is now FDA cleared for arrhythmia assessment, with additional FDA review underway for its 12-lead ECG synthesis software for the same indication. A recent partnership with AccurKardia enhances HeartBeam’s arrhythmia solution with an FDA-cleared automated rhythm interpretation software. HeartBeam holds 20 issued patents,…

FridayJun 13, 2025 10:00 am

New Study Shows TTFields Amplify Immune Attack Against Brain Cancer

Breakthrough research conducted by a team at the University of Southern California (USC) has found that electric fields, administered through a device placed on a patient’s scalp, can supercharge the immune system’s ability to combat glioblastoma and increase the survival time of the patient. These benefits for patients were attained after combining the electric fields with chemotherapy and immunotherapy treatments. Glioblastoma is a brain cancer whose prognosis is very poor because it grows rapidly and the existing treatments usually have a minimum beneficial impact upon the progress of the cancer. On average, patients with this type of brain tumor survive…

ThursdayJun 12, 2025 10:00 am

Study Finds Kids with MS Biologically Age Faster Than Those Without It

New research conducted by UC San Diego researchers has revealed that adolescents and children having multiple sclerosis exhibit accelerated biological ageing. These findings were published in the journal Neurology. This study suggests that the changes linked to ageing could be happening earlier than had initially been thought among patients with MS. MS, a chronic disease affecting the CNS (central nervous system), largely exhibits its effects on the optic nerves, the brain and spinal cord. Most research on this disease has focused on adults, and this UC San Diego study is the first to investigate biological ageing in younger individuals afflicted…

ThursdayJun 12, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development

Financial momentum for Nutriband is indicated by its recent Q1 financial report Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report AVERSA(TM) Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates. Financial momentum for Nutriband is…

ThursdayJun 12, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is facing a severe ketamine shortage, prompting NRx to seek priority FDA review. NRX-100 eliminates benzethonium chloride, aligning with U.S. health initiatives to remove toxic preservatives. The company plans to petition the FDA to remove benzethonium chloride from all intravenous ketamine products. The filing complements the company’s NDA for NRX-100 for suicidal depression, with a PDUFA date expected in late 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation…

WednesdayJun 11, 2025 10:30 am

Adageis Allows Healthcare Providers Maximum Value-Based Care Revenue with Simplicity and Visibility

The company offers a simple, AI-powered platform that helps providers identify their most valuable services, bringing clarity to complex insurance contracts, and highlighting where clinics can optimize revenue. The platform’s AI analytics help to identify high-risk patients and close care gaps efficiently, while letting providers track financial performance over time, aligning income with quality of care. Adageis continues to grow and expects to cover 580,000 patient lives by Q2 2025 and reach $100,000 in monthly recurring revenue. As healthcare shifts further toward value-based care, one challenge continues to frustrate providers: understanding how care quality translates into financial outcomes. Adageis, a…

WednesdayJun 11, 2025 9:45 am

Smart Hospitality: SkyTech Robots and the Future of U.S. Service Innovation Through AI

As the world watches Foxconn and NVIDIA deploy smart robotics in Taiwan’s cutting-edge hospitals, the same technology driven future is quietly taking shape across the American hospitality industry. Led by companies like SkyTech Automated Solutions, a wholly owned subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF). Foxconn's recent unveiling of its NVIDIA-powered hospital robots signals a monumental shift: combining real-time AI with robotics to improve labor efficiency, safety, and service personalization. The smart hospital model represents not just a technological leap, but a redefinition of how service delivery is imagined in labor-intensive environments. SkyTech is bringing that same revolution to the…

WednesdayJun 11, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline. The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL. Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations. Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways. With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support…